What is the clinical evidence from this study?

Intervention: Interleukin-3 (IL-3) and Interleukin-6 (IL-6) vs. Control. Primary outcome: Platelet levels.

January 1, 1991Blood

Multiple in vivo effects of interleukin-3 and interleukin-6 on murine megakaryocytopoiesis

View Full Paper

Ask AI

Bookmark

Key result

Administration of IL-6 and IL-3 in mice stimulated platelet production in vivo, with combined effects being approximately additive (61% increase in platelet levels).

Authors

PCPA CarringtonUniversity of California, San Francisco RHRJ HillMRC Laboratory of Molecular Biology PSPE StenbergStanford University

Discussion

Member takes

Implication

Hypothesis-generating for cytokine approaches to thrombocytopenia; human studies required before clinical consideration.

PICO

Population

Mice treated with IL-3, IL-6, or both to evaluate megakaryocytopoiesis and thrombopoiesis over a 30-day period.

Intervention / Comparator

Interleukin-3 (IL-3) and Interleukin-6 (IL-6) vs Control (IL-6: 14 injections of 5,000 units over 102 hours; IL-3: 8 injections of 80,000 units over 54 hours)

Primary Outcome

Platelet levels

Cite This Study

Carrington et al. (1991) studied this question. Interleukin-3 (IL-3) and Interleukin-6 (IL-6) vs. Control was evaluated on Platelet levels. Administration of IL-6 and IL-3 in mice stimulated platelet production in vivo, with combined effects being approximately additive (61% increase in platelet levels).

synapsesocial.com/papers/6a9f79978c462a8aba107eeb https://doi.org/10.1182/blood.v77.1.34.34

View Full Paper

Ask AI

Bookmark

Multiple in vivo effects of interleukin-3 and interleukin-6 on murine megakaryocytopoiesis

Discussion

Member takes

Implication

PICO

Cite This Study

Multiple in vivo effects of interleukin-3 and interleukin-6 on murine megakaryocytopoiesis

Discussion

Member takes

Implication

PICO

Cite This Study

Also Consider

Also Consider